Literature DB >> 11402147

Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease.

V M Lee1, J Q Trojanowski.   

Abstract

Because filamentous neuronal tau inclusions are neuropathologic hallmarks of Pick's disease and a number of other neurodegenerative disorders known as tauopathies, the authors generated lines of transgenic (Tg) mice that overexpress the shortest human tau isoform in the CNS. These Tg mice accumulated argyrophilic and filamentous tau immunoreactive neuronal inclusions with age in cortex and brainstem as well as in spinal cord, where these inclusions were most abundant and associated with gliosis. The ventral roots of affected spinal cord segments showed axonal degeneration, whereas residual axons exhibited reduced microtubules and reduced fast axonal transport. The inclusions were composed of 10 to 20 nm tau immunopositive straight filaments. In addition, the Tg mice developed age-related motor weakness as well as progressive hyperphosphorylation and decreased solubility of brain and spinal cord tau proteins. Thus, these Tg mice recapitulate phenotypic features of human tauopathies. In this article the authors review the phenotype of these Tg mice and discuss how the availability of relevant animal model of tauopathies will facilitate discovery of more effective therapies to treat Pick's disease and related disorders characterized by filamentous tau pathology in selectively vulnerable regions of the CNS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402147     DOI: 10.1212/wnl.56.suppl_4.s26

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Tau alternative splicing and frontotemporal dementia.

Authors:  Amar Kar; David Kuo; Rongqiao He; Jiawei Zhou; Jane Y Wu
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

Review 2.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

Review 3.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

4.  Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention.

Authors:  Aaron Carman; Sarah Kishinevsky; John Koren; Wenjie Lou; Gabriela Chiosis
Journal:  J Alzheimers Dis Parkinsonism       Date:  2013-04

Review 5.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.